Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Civitas’ Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant

This article was originally published in The Pink Sheet Daily

Executive Summary

Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.

You may also be interested in...



Disease Foundations Are Finding Their Way In New Research Relationships

Disease foundations have realized that funding basic research is not enough to serve their patient groups, but forging those later-stage relationships can be tricky and all parties involved are developing new flexibilities, panelists at the BIO annual meeting said June 21 in Boston.

As Pharma Looks Beyond The Molecule For Innovation, Can VCs Take Advantage?

Big Pharma’s growing interest in innovation beyond the molecule that improves health outcomes could provide new opportunities for biotechs and their venture capital backers, but in many areas investors have approached cautiously.

Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition

Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073092

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel